Association between Parkinson disease and risk of cancer in Taiwan

JAMA Oncology

Volumn 1, Issue 5, 2015, Pages 633-640

  Lin, Pei Ying ^a,b,c   Chang, Shih Ni ^d,e   Hsiao, Tzu Hung ^d   Huang, Bo Tsang ^b,c   Lin, Ching Heng ^a,d   Yang, Pan Chyr ^b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; EPIDEMIOLOGY; ETHNOLOGY; FACTUAL DATABASE; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TAIWAN; TIME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84964693236     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1752     Document Type: Article

References (58)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793.
2. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet. 2007;16 Spec No. 2(Spec No 2):R183-R194.
3. Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(1): a008888.
4. Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012;7 (9):e45183.
5. Bethge N, Lothe RA, Honne H, et al. Colorectal cancer DNA methylation marker panel validated with high performance in non-Hodgkin lymphoma. Epigenetics. 2014;9(3):428-436.
6. Veeriah S, Taylor BS, Meng S, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010;42(1):77-82.
7. Fujiwara M, Marusawa H, Wang HQ, et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene. 2008;27(46):6002-6011.
8. Gong Y, Zack TI, Morris LG, et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet. 2014;46(6): 588-594.
9. Xiong D, Wang Y, Kupert E, et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet. 2015;96(2):301-308.
10. Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 2011;71(5):1836-1848.
11. O'Flanagan CH, Morais VA, Wurst W, De Strooper B, O'Neill C. The Parkinson's gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes. Oncogene. 2015;34 (11):1363-1374.
12. Tsuchiya B, Iwaya K, Kohno N, et al. Clinical significance of DJ-1 as a secretory molecule: retrospective study of DJ-1 expression at mRNA and protein levels in ductal carcinoma of the breast. Histopathology. 2012;61(1):69-77.
13. Ismail IA, Kang HS, Lee HJ, Kim JK, Hong SH. DJ-1 upregulates breast cancer cell invasion by repressing KLF17 expression. Br J Cancer. 2014;110 (5):1298-1306.
14. Looyenga BD, Furge KA, Dykema KJ, et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci USA. 2011;108(4):1439-1444.
15. Lewis PA, Manzoni C. LRRK2 and human disease: a complicated question or a question of complexes? Sci Signal. 2012;5(207):pe2.
16. Agalliu I, San Luciano M, Mirelman A, et al. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol. 2015;72(1):58-65.
17. Laman H, Funes JM, Ye H, et al. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6. EMBO J. 2005;24(17): 3104-3116.
18. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011;26(suppl 1):S1-S58.
19. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21(5):697-707.
20. Driver JA. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology. 2014;15(6):547-557.
21. Wirdefeldt K, Weibull CE, Chen H, et al. Parkinson's disease and cancer: A register-based family study. Am J Epidemiol. 2014;179(1):85-94.
22. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer. 2005;92(1):201-205.
23. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol. 2012;69(12):1572-1577.
24. Ong EL, Goldacre R, Goldacre M. Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study. Eur J Cancer. 2014;50(14):2456-2462.
25. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer. 2014;14(12):786-800.
26. Eifert C, Powers RS. From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer. 2012;12(8): 572-578.
27. Maris JM, Knudson AG. Revisiting tissue specificity of germline cancer predisposing mutations. Nat Rev Cancer. 2015;15(2):65-66.
28. Lesage S, Dürr A, Tazir M, et al; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006;354(4):422-423.
29. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006;354(4):424-425.
30. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early-and late-onset Parkinson disease. Neurology. 2006;67(10):1786-1791.
31. Zabetian CP, Hutter CM, Yearout D, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet. 2006;79(4): 752-758.
32. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304 (5676):1497-1500.
33. Shan Y, Eastwood MP, Zhang X, et al. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell. 2012;149(4):860-870.
34. Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci USA. 2013;110(38):E3595-E3604.
35. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
36. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-2246.
37. Abdulla MA, Ahmed I, Assawamakin A, et al; HUGO Pan-Asian SNP Consortium; Indian Genome Variation Consortium. Mapping human genetic diversity in Asia. Science. 2009;326(5959):1541-1545.
38. Lin CH, Sheu WHH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273(1):102-110.
39. Taiwan National Cancer Registry Database. http://tcr.cph.ntu.edu.tw/main.php?Page=N1. Accessed May 17, 2015.
40. Constantinescu R, Romer M, Kieburtz K; DATATOP Investigators of the Parkinson Study Group. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord. 2007;22 (5):720-722.
41. Schwid SR, Bausch J, Oakes D, et al; PSG PRECEPT Investigators. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010;25(12):1801-1808.
42. Constantinescu R, Elm J, Auinger P, et al; NET-PD Investigators. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord. 2014;29(2):263-265.
43. Tanaka H, Tsukuma H, Tomita S, et al. Time trends of incidence for cutaneous melanoma among the Japanese population: an analysis of Osaka Cancer Registry data, 1964-95. J Epidemiol. 1999;9(6)(suppl):S129-S135.
44. Paisán-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology. 2010;75(18):1653-1655.
45. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009;73(16): 1286-1291.
46. Annual Report of Health Promotion Administration. Taiwan: Ministry of Health and Welfare; 2014.
47. Frigerio R, Sanft KR, Grossardt BR, et al. Chemical exposures and Parkinson's disease: a population-based case-control study. Mov Disord. 2006;21(10):1688-1692.
48. Barnhill LM, Bronstein JM. Pesticides and Parkinson's disease: is it in your genes? Neurodegener Dis Manag. 2014;4(3):197-200.
49. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499-2509.
50. Wu IC, Wu CC, Lu CY, et al. Substance use (alcohol, areca nut and cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One. 2013;8(2):e55834.
51. Teng YH, Tan WJ, Thike AA, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13(2):R35.
52. Jacot W, Lopez-Crapez E, Thezenas S, et al. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res. 2011;13(6):R133.
53. Secq V, Villeret J, Fina F, et al. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations. Br J Cancer. 2014;110(4):1045-1052.
54. Fallon L, Bélanger CM, Corera AT, et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol. 2006;8(8):834-842.
55. Gómez-Suaga P, Rivero-Ríos P, Fdez E, et al. LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum Mol Genet. 2014;23 (25):6779-6796.
56. Hinkle DA, Mullett SJ, Gabris BE, Hamilton RL. DJ-1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification. Neuropathology. 2011;31(1):29-37.
57. Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577, 013 participants of 50 observational studies. Psychother Psychosom. 2014;83(2):89-105.
58. Benito-León J, Bermejo-Pareja F, Morales-González JM, et al; Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004;62(5):734-741.